Stem Pharm, Inc

stempharm.com

Stem Pharm offers unique biomaterials for cell and tissue manufacturing. Applications include medical devices for drug discovery, cell therapy, and regenerative medicine. Stem Pharm's synthetic biomaterials support the optimization of cell expansion and differentiation, human tissue formation and cell/tissue delivery applications. Through control of the biomaterial properties (e.g. mechanical stiffness, cell adhesion, degradability), and utilizing chemistries that maintain cellular health and function, we provide cell-specific biomaterials to researchers and clinicians to fill unmet needs in their workflows. Currently, cell and tissue manufacturing processes often rely on animal-derived biomaterials that are complex and variable in nature and problematic for human in vivo applications due to potential pathogen transmission or an immunogenic response. Our materials are synthetic, defined, and optimized to produce functional cells and tissues and deliver them to areas of clinical need.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

COSMOSID® ENTERS MICROBIOME PARTNERSHIP WITH LOCUS BIOSCIENCES

CosmosID | June 22, 2022

news image

CosmosID®, an American provider of end-to-end microbiome platforms and award-winning metagenomics services, announced entering into a microbiome partnership with a clinical-stage biotechnology company developing a new class of precision-engineered bacteriophage treatments, Locus Biosciences, Inc. With this partnership, CosmosID focuses on providing its GCP-compliant and CLIA-certified laboratory services for Locus' clinical trial initiatives in the microbiome field. ...

Read More

PRECISION VIROLOGICS AND BHARAT BIOTECH JOINTLY OBTAIN RIGHTS TO INTRANASAL COVID-19 VACCINE TECHNOLOGY

Precision Virologics | September 23, 2020

news image

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Read More

GENETIC TESTING MARKET TO SET NEW GROWTH STORY: TRANSGENOMIC, GE HEALTHCARE, 23 & ME

EIN News | April 16, 2020

news image

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

Read More

MEDTECH

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

news image

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More
news image

MEDICAL

COSMOSID® ENTERS MICROBIOME PARTNERSHIP WITH LOCUS BIOSCIENCES

CosmosID | June 22, 2022

CosmosID®, an American provider of end-to-end microbiome platforms and award-winning metagenomics services, announced entering into a microbiome partnership with a clinical-stage biotechnology company developing a new class of precision-engineered bacteriophage treatments, Locus Biosciences, Inc. With this partnership, CosmosID focuses on providing its GCP-compliant and CLIA-certified laboratory services for Locus' clinical trial initiatives in the microbiome field. ...

Read More
news image

PRECISION VIROLOGICS AND BHARAT BIOTECH JOINTLY OBTAIN RIGHTS TO INTRANASAL COVID-19 VACCINE TECHNOLOGY

Precision Virologics | September 23, 2020

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Read More
news image

GENETIC TESTING MARKET TO SET NEW GROWTH STORY: TRANSGENOMIC, GE HEALTHCARE, 23 & ME

EIN News | April 16, 2020

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

Read More
news image

MEDTECH

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More